This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain. IBRANCE® (palbociclib) Prescribing Information for Great Britain click here. IBRANCE® (palbociclib) Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

Title

COVID 19 Pandemic :  Latest information and updates on Adapting Breast Cancer Care here

IBRANCE®

Confidence Built on Evidence1 ​​​​​​​

Dosing

Dosing and monitoring requirements for IBRANCE®

More information

Efficacy

IBRANCE® PALOMA-2 and PALOMA-3 Clinical Trial Results, including efficacy and safety outcomes

Learn More

Safety Profile

Important safety information and safety outcomes from IBRANCE® PALOMA Clinical Trials

See Results

IBRANCE® (palbociclib) is indicated for the treatment of HR+/HER2- locally advanced or mBC in combination with an AI or with fulvestrant in women who have received prior ET. In pre- or peri-menopausal women, the ET should be combined with an LHRH agonist.1 

IBRANCE® is the first cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved for HR+/HER2- locally advanced and metastatic breast cancer.1-2

As a 1st line therapy in HR+/HER2- locally advanced and metastatic breast cancer, IBRANCE® + letrozole has demonstrated >2 years median progression free survival vs letrozole plus placebo alone in the PALOMA-2 study.2-3 IBRANCE® plus fulvestrant delivers more than double the mPFS compared with fulvestrant monotherapy, 11.2 months with IBRANCE® plus fulvestrant vs. 4.6 months with fulvestrant plus placebo.4-5

Real World Evidence

Real-world evidence for IBRANCE® (palbociclib) in advanced Breast Cancer

View

Support for Your Patients

IBRANCE® (palbociclib) Resources to support your patients including a Patient Brochure and Dosing Cards

View Resources


AI : Aromatase Inhibitor,  ET : Endocrine Therapy,  HR+/HER2– : Hormone Receptor Positive / Human Epidermal Growth Factor Receptor 2 Negative,  LHRH : Luteinizing Hormone-Releasing Hormone,  mBC : metastatic Breast Cancer

 ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

References
  1. IBRANCE® Summary of Product Characteristics for Great Britain click here. IBRANCE® Summary of Product Characteristics for Northern Ireland click here.
  2. Finn RS, et al. N Engl J Med. 2016;375(20):1925-1936.
  3. Rugo HS, et al. Breast Cancer Res Treat. 2019;174:719–29.
  4. Cristofanilli M, et al. Lancet Oncol. 2016;17:425–39.
  5. Turner NC et al. N Engl J Med. 2018;379:1926–36.
PP-IBR-GBR-3726. July 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No